FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180345462> ?p ?o ?g. }

• W3180345462 endingPage "7508" @default.
• W3180345462 startingPage "7508" @default.
• W3180345462 abstract "The KRAS mutation is one of the leading driver mutations in colorectal cancer (CRC), and it is usually associated with poor prognosis and drug resistance. Therapies targeting the epidermal growth factor receptor (EFGR) are widely used for end-stage CRC. However, patients with KRAS mutant genes cannot benefit from this therapy because of Ras signaling activation by KRAS mutant genes. Our previous study revealed the anti-proliferative effect of 4-acetyl-antroquinonol B (4-AAQB) on CRC cells, but whether the drug is effective in KRAS-mutant CRC remains unknown. We screened CRC cell lines harboring the KRAS mutation, namely G12A, G12C, G12V and G13D, with one wild type cell line as the control; SW1463 and Caco-2 cell lines were used for further experiments. Sulforhodamine B assays, together with the clonogenicity and invasion assay, revealed that KRAS-mutant SW1463 cells were resistant to cetuximab; however, 4-AAQB treatment effectively resensitized CRC cells to cetuximab through the reduction of colony formation, invasion, and tumorsphere generation and of oncogenic KRAS signaling cascade of CRC cells. Thus, inducing cells with 4-AAQB before cetuximab therapy could resensitize KRAS-mutant, but not wild-type, cells to cetuximab. Therefore, we hypothesized that 4-AAQB can inhibit KRAS. In silico analysis of the publicly available GEO (GSE66548) dataset of KRAS-mutated versus KRAS wild-type CRC patients confirmed that miR-193a-3p was significantly downregulated in the former compared with the latter patient population. Overexpression of miR-193a-3p considerably reduced the oncogenicity of both CRC cells. Furthermore, KRAS is a key target of miR-193a-3p. In vivo treatment with the combination of 4-AAQB and cetuximab significantly reduced the tumor burden of a xenograft mice model through the reduction of the expression of oncogenic markers (EGFR) and p-MEK, p-ERK, and c-RAF/p-c-RAF signaling, with the simultaneous induction of miR-193a-3p expression in the plasma. In summary, our findings provide strong evidence regarding the therapeutic effect of 4-AAQB on KRAS-mutant CRC cells. Furthermore, 4-AAQB effectively inhibits Ras singling in CRC cells, through which KRAS-mutant CRC can be resensitized to cetuximab." @default.
• W3180345462 created "2021-07-19" @default.
• W3180345462 creator A5006041425 @default.
• W3180345462 creator A5042195821 @default.
• W3180345462 creator A5050232319 @default.
• W3180345462 creator A5056734566 @default.
• W3180345462 creator A5062638070 @default.
• W3180345462 creator A5068566236 @default.
• W3180345462 creator A5074365129 @default.
• W3180345462 creator A5076657463 @default.
• W3180345462 date "2021-07-14" @default.
• W3180345462 modified "2023-09-25" @default.
• W3180345462 title "4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis" @default.
• W3180345462 cites W1078787812 @default.
• W3180345462 cites W1757407923 @default.
• W3180345462 cites W1966369019 @default.
• W3180345462 cites W1981189257 @default.
• W3180345462 cites W1999503941 @default.
• W3180345462 cites W2011826559 @default.
• W3180345462 cites W2042995204 @default.
• W3180345462 cites W2059167706 @default.
• W3180345462 cites W2066912318 @default.
• W3180345462 cites W2075722667 @default.
• W3180345462 cites W2096439168 @default.
• W3180345462 cites W2120490763 @default.
• W3180345462 cites W2132834292 @default.
• W3180345462 cites W2134519717 @default.
• W3180345462 cites W2145099358 @default.
• W3180345462 cites W2157824687 @default.
• W3180345462 cites W2164837623 @default.
• W3180345462 cites W2524554744 @default.
• W3180345462 cites W2560100286 @default.
• W3180345462 cites W2561259078 @default.
• W3180345462 cites W2599421998 @default.
• W3180345462 cites W2607413117 @default.
• W3180345462 cites W2767911431 @default.
• W3180345462 cites W2768833785 @default.
• W3180345462 cites W2791529256 @default.
• W3180345462 cites W2800379950 @default.
• W3180345462 cites W2802981934 @default.
• W3180345462 cites W2884985642 @default.
• W3180345462 cites W2891181915 @default.
• W3180345462 cites W2901651432 @default.
• W3180345462 cites W2942537220 @default.
• W3180345462 cites W2953074487 @default.
• W3180345462 cites W2964918777 @default.
• W3180345462 cites W2974416662 @default.
• W3180345462 cites W2982152684 @default.
• W3180345462 cites W2982321167 @default.
• W3180345462 cites W3000124456 @default.
• W3180345462 cites W3014713533 @default.
• W3180345462 cites W3037750477 @default.
• W3180345462 cites W3082531223 @default.
• W3180345462 cites W3146066551 @default.
• W3180345462 doi "https://doi.org/10.3390/ijms22147508" @default.
• W3180345462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8307961" @default.
• W3180345462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34299137" @default.
• W3180345462 hasPublicationYear "2021" @default.
• W3180345462 type Work @default.
• W3180345462 sameAs 3180345462 @default.
• W3180345462 citedByCount "7" @default.
• W3180345462 countsByYear W31803454622022 @default.
• W3180345462 countsByYear W31803454622023 @default.
• W3180345462 crossrefType "journal-article" @default.
• W3180345462 hasAuthorship W3180345462A5006041425 @default.
• W3180345462 hasAuthorship W3180345462A5042195821 @default.
• W3180345462 hasAuthorship W3180345462A5050232319 @default.
• W3180345462 hasAuthorship W3180345462A5056734566 @default.
• W3180345462 hasAuthorship W3180345462A5062638070 @default.
• W3180345462 hasAuthorship W3180345462A5068566236 @default.
• W3180345462 hasAuthorship W3180345462A5074365129 @default.
• W3180345462 hasAuthorship W3180345462A5076657463 @default.
• W3180345462 hasBestOaLocation W31803454621 @default.
• W3180345462 hasConcept C104317684 @default.
• W3180345462 hasConcept C121608353 @default.
• W3180345462 hasConcept C143065580 @default.
• W3180345462 hasConcept C207583985 @default.
• W3180345462 hasConcept C2779438470 @default.
• W3180345462 hasConcept C2779998722 @default.
• W3180345462 hasConcept C2781187634 @default.
• W3180345462 hasConcept C2781230642 @default.
• W3180345462 hasConcept C2908647359 @default.
• W3180345462 hasConcept C502942594 @default.
• W3180345462 hasConcept C526805850 @default.
• W3180345462 hasConcept C54355233 @default.
• W3180345462 hasConcept C71924100 @default.
• W3180345462 hasConcept C86803240 @default.
• W3180345462 hasConcept C99454951 @default.
• W3180345462 hasConceptScore W3180345462C104317684 @default.
• W3180345462 hasConceptScore W3180345462C121608353 @default.
• W3180345462 hasConceptScore W3180345462C143065580 @default.
• W3180345462 hasConceptScore W3180345462C207583985 @default.
• W3180345462 hasConceptScore W3180345462C2779438470 @default.
• W3180345462 hasConceptScore W3180345462C2779998722 @default.
• W3180345462 hasConceptScore W3180345462C2781187634 @default.
• W3180345462 hasConceptScore W3180345462C2781230642 @default.
• W3180345462 hasConceptScore W3180345462C2908647359 @default.
• W3180345462 hasConceptScore W3180345462C502942594 @default.

• next